2/6
07:00 pm
jnj
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
Low
Report
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
2/4
01:16 pm
jnj
BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here's Why [Yahoo! Finance]
Low
Report
BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here's Why [Yahoo! Finance]
2/4
11:48 am
jnj
Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? [Yahoo! Finance]
Neutral
Report
Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? [Yahoo! Finance]
2/3
10:12 pm
jnj
Alcon's Precision7 Weekly Lenses Test Comfort Claims And Growth Hopes [Yahoo! Finance]
Low
Report
Alcon's Precision7 Weekly Lenses Test Comfort Claims And Growth Hopes [Yahoo! Finance]
2/3
11:37 am
jnj
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates [Yahoo! Finance]
Low
Report
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates [Yahoo! Finance]
2/3
11:33 am
jnj
Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says [Yahoo! Finance]
Low
Report
Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says [Yahoo! Finance]
2/3
10:20 am
jnj
Toptal Ranked #1 Most Reliable Professional Services Company in America by Newsweek [Yahoo! Finance]
Low
Report
Toptal Ranked #1 Most Reliable Professional Services Company in America by Newsweek [Yahoo! Finance]
2/3
09:42 am
jnj
Johnson & Johnson (NYSE:JNJ) had its price target raised by analysts at Royal Bank Of Canada from $240.00 to $255.00. They now have an "outperform" rating on the stock.
Low
Report
Johnson & Johnson (NYSE:JNJ) had its price target raised by analysts at Royal Bank Of Canada from $240.00 to $255.00. They now have an "outperform" rating on the stock.
2/3
07:23 am
jnj
Bristol Myers Squibb Introduces "Change the Target. Change What's Possible." to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care [Yahoo! Finance]
Low
Report
Bristol Myers Squibb Introduces "Change the Target. Change What's Possible." to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care [Yahoo! Finance]
2/3
03:12 am
jnj
Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland [Yahoo! Finance]
Low
Report
Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland [Yahoo! Finance]
2/2
04:34 pm
jnj
Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
2/2
02:43 pm
jnj
[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]
Low
Report
[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]
2/2
10:00 am
jnj
Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 [Yahoo! Finance]
Low
Report
Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 [Yahoo! Finance]
2/2
08:13 am
jnj
Santé Ventures Raises $330 Million for Fifth Fund to Advance Breakthrough Healthcare Innovation [Yahoo! Finance]
Low
Report
Santé Ventures Raises $330 Million for Fifth Fund to Advance Breakthrough Healthcare Innovation [Yahoo! Finance]
2/2
08:11 am
jnj
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months [Yahoo! Finance]
Low
Report
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months [Yahoo! Finance]
2/1
10:36 am
jnj
Ariel Focus Fund Q4 2025 Portfolio Review [Seeking Alpha]
Low
Report
Ariel Focus Fund Q4 2025 Portfolio Review [Seeking Alpha]
2/1
12:22 am
jnj
Johnson & Johnson's Myeloma Approval And What It May Mean For JNJ Stock [Yahoo! Finance]
Low
Report
Johnson & Johnson's Myeloma Approval And What It May Mean For JNJ Stock [Yahoo! Finance]
1/31
07:03 pm
jnj
Is Johnson & Johnson (JNJ) The Most Profitable Healthcare Stock To Buy? [Yahoo! Finance]
Low
Report
Is Johnson & Johnson (JNJ) The Most Profitable Healthcare Stock To Buy? [Yahoo! Finance]
1/31
03:52 pm
jnj
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations [Yahoo! Finance]
Low
Report
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations [Yahoo! Finance]
1/31
11:06 am
jnj
Insider trades: JNJ, Intel, IBM among notable names [Seeking Alpha]
Low
Report
Insider trades: JNJ, Intel, IBM among notable names [Seeking Alpha]
1/31
09:37 am
jnj
Johnson & Johnson (NYSE:JNJ) had its price target raised by analysts at HSBC Holdings plc from $240.00 to $265.00. They now have a "buy" rating on the stock.
Low
Report
Johnson & Johnson (NYSE:JNJ) had its price target raised by analysts at HSBC Holdings plc from $240.00 to $265.00. They now have a "buy" rating on the stock.
1/30
10:53 pm
jnj
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? [Yahoo! Finance]
Low
Report
This Top Dividend Stock Could Achieve a Major Milestone This Year. Is It a Buy? [Yahoo! Finance]
1/30
02:50 pm
jnj
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over [Seeking Alpha]
Low
Report
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over [Seeking Alpha]
1/30
12:44 pm
jnj
What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock? [Yahoo! Finance]
Low
Report
What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock? [Yahoo! Finance]
1/30
09:41 am
jnj
Johnson & Johnson (NYSE:JNJ) had its price target raised by analysts at Daiwa Capital Markets from $203.00 to $237.00. They now have an "outperform" rating on the stock.
Low
Report
Johnson & Johnson (NYSE:JNJ) had its price target raised by analysts at Daiwa Capital Markets from $203.00 to $237.00. They now have an "outperform" rating on the stock.